On this page
What is Diabetic Nephropathy?
Diabetic nephropathy, also known as diabetic kidney disease (DKD), is a serious and progressive complication of both type 1 and type 2 diabetes mellitus that impairs the kidneys’ ability to filter waste products and excess fluid from the body. According to epidemiological data, approximately 1 in 3 people with diabetes develops diabetic nephropathy, making it one of the most prevalent and clinically significant long-term complications of the disease.
The condition typically progresses silently in its early stages, without any noticeable symptoms or warning signs. It is only in more advanced stages that overt manifestations emerge, potentially including:
- Difficulty controlling blood pressure (hypertension)
- Protein in the urine (proteinuria)
- Swelling (edema) of the feet, ankles, hands, and/or eyelids
- Increased urinary frequency
- Mental confusion or difficulty concentrating
- Shortness of breath (dyspnea)
- Loss of appetite
- Nausea and vomiting
- Persistent itching (pruritus)
- Fatigue and weakness
The condition can be detected through blood and urine laboratory tests, often before symptoms appear, making routine monitoring an essential component of diabetes management.
The most effective strategy for preventing or delaying the onset of diabetic nephropathy is maintaining a healthy lifestyle combined with rigorous control of blood glucose levels (glycemia) and blood pressure. Early identification and treatment can slow disease progression and significantly reduce the risk of complications.
In advanced stages, diabetic nephropathy can lead to end-stage renal disease (renal failure), a life-threatening condition requiring dialysis or kidney transplantation.
Causes
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in developed countries. It is classified as a microvascular complication of diabetes, meaning it arises from damage to the small blood vessels, and occurs in both type 1 and type 2 diabetes mellitus.
Pathophysiology: How Does Diabetes Damage the Kidneys?
Each kidney contains approximately one million tiny filtering units called nephrons. Each nephron includes a glomerulus, a microscopic cluster of capillaries, through which blood is filtered. Persistent hyperglycemia (chronically elevated blood glucose) damages these delicate blood vessels through several interconnected mechanisms:
- Glomerular hypertension and hyperfiltration: In the early stages of diabetes, the kidneys actually over-filter blood in compensation, which paradoxically accelerates structural damage over time.
- Advanced glycation end-products (AGEs): Excess glucose chemically modifies proteins and lipids, forming AGEs that deposit in the glomerular basement membrane, thickening it and impairing filtration.
- Oxidative stress and inflammation: Chronic hyperglycemia generates reactive oxygen species and activates pro-inflammatory pathways that damage endothelial and mesangial cells.
- Activation of the renin-angiotensin-aldosterone system (RAAS): This leads to increased intraglomerular pressure and promotes fibrosis.
- Nodular glomerulosclerosis (Kimmelstiel-Wilson lesions): A pathognomonic finding in advanced diabetic nephropathy, nodules of extracellular matrix that progressively replace functional glomerular tissue.
Hypertension, itself a common complication and frequent comorbidity of diabetes, further accelerates this damage, creating a self-perpetuating cycle in which kidney disease worsens blood pressure control, and vice versa.
Risk Factors
The two most powerful modifiable risk factors for the development and progression of diabetic nephropathy are:
- Poor glycemic control (chronically elevated HbA1c)
- Poor blood pressure control
Additional risk factors that increase susceptibility include:
- Male sex (men are at slightly higher risk than women)
- Family history of hypertension or cardiovascular events in first-degree relatives
- Obesity: particularly central (abdominal) adiposity
- Smoking: directly toxic to renal vasculature and associated with accelerated progression of nephropathy
- Hyperlipidemia (high cholesterol): dyslipidemia contributes to glomerular damage and cardiovascular risk
- Duration of diabetes: the longer a person has had diabetes, the greater the cumulative risk of kidney damage
- Ethnicity: South Asian, African American, and Hispanic/Latino populations are at disproportionately higher risk
Symptoms
The structural and functional changes that occur progressively in the kidneys of patients with diabetic nephropathy evolve through well-defined stages:
Early Stage: Silent Progression
In the early stages, diabetic nephropathy causes no symptoms. The first detectable abnormality is typically the development of microalbuminuria, a small but abnormal amount of the protein albumin leaking into the urine, detectable only by sensitive laboratory tests. At this stage, kidney function (as measured by the estimated glomerular filtration rate, or eGFR) may still be normal or even supranormal (due to hyperfiltration).
Routine monitoring at this stage may reveal:
- Elevated serum creatinine: an indirect marker of reduced kidney filtration
- Microalbuminuria: 30–300 mg of albumin per gram of creatinine in the urine
Progressive Stage: Emerging Signs
As nephropathy advances, clinically detectable signs begin to appear:
- Proteinuria (macroalbuminuria, >300 mg/day): Protein leakage into the urine may become visible as foamy or frothy urine, an important and often underappreciated warning sign that patients themselves may notice.
- Hypertension: Either developing for the first time or significantly worsening, as the kidneys lose their ability to regulate sodium excretion and blood pressure.
- Progressive reduction in kidney function: Declining eGFR reflects the ongoing loss of functional nephrons.
Advanced Stage: Nephrotic Syndrome and Uremia
In more advanced disease, patients may develop the classic features of nephrotic syndrome:
- Proteinuria (often massively elevated, >3.5 g/day)
- Hypoalbuminemia: low blood albumin levels due to urinary protein losses
- Hypercholesterolemia: the liver compensates for low albumin by increasing lipid synthesis
- Generalized edema: fluid shifts from the bloodstream into tissues due to reduced oncotic pressure
As kidney function deteriorates further, symptoms of uremia (the toxic accumulation of waste products in the blood) emerge:
- Fatigue and weakness
- Nausea and vomiting
- Loss of appetite
- Mental confusion
- Shortness of breath
- Persistent itching (due to phosphate retention)
- Swelling of the ankles, feet, and hands
Why Does Blood Sugar Appear to Improve at the Onset of Nephropathy?
This is a clinically important and frequently misunderstood phenomenon that can catch both patients and physicians off guard.
The kidneys play a critical role in clearing insulin from the bloodstream. Insulin is the hormone responsible for reducing blood glucose levels. When kidney function is impaired, insulin is metabolized and excreted more slowly, meaning it remains active in the body for longer periods than normal.
As a result, patients on insulin therapy may find they need progressively smaller insulin doses to maintain target blood glucose levels, and may even experience more frequent episodes of hypoglycemia (low blood sugar) if their dosing is not adjusted downward.
This same principle applies to other antidiabetic medications that are primarily cleared by the kidneys (e.g., certain sulfonylureas, some GLP-1 receptor agonists, SGLT2 inhibitors). As kidney function declines, these drugs accumulate and their effects intensify or their safety profile changes.
Key clinical implication: An apparent “improvement” in glycemic control in a patient with longstanding diabetes, without any change in diet or medication, should raise suspicion of declining kidney function rather than be interpreted as a positive development. Physicians managing diabetic patients should routinely monitor renal function and adjust medication regimens accordingly.
Diagnosis
The Diagnostic Standard: Albuminuria Testing
Diabetic nephropathy is diagnosed when albumin is detected in the urine (albuminuria) on at least two separate occasions, with tests spaced at least three months apart. This is because transient albuminuria can result from non-renal causes such as urinary tract infections, vigorous exercise, or febrile illness.
The preferred sample for testing is a first morning urine specimen (spot urine albumin-to-creatinine ratio, or UACR), which minimizes the effect of postural (orthostatic) proteinuria. Alternatively, a 24-hour urine collection showing albumin excretion above 300 mg/day confirms macroalbuminuria.
Staging by Albuminuria and eGFR
| Stage | UACR | eGFR (mL/min/1.73 m²) | Clinical significance |
|---|---|---|---|
| Normal | <30 mg/g | ≥90 | No nephropathy |
| Microalbuminuria | 30–300 mg/g | Variable | Early nephropathy, the critical intervention window |
| Macroalbuminuria | >300 mg/g | Often reduced | Established nephropathy |
| End-stage renal disease | Variable | <15 | Requires dialysis or transplant |
Excluding Other Causes
Before attributing albuminuria to diabetic nephropathy, it is essential to rule out a urinary tract infection (UTI) as the cause of protein leakage, using a standard urine analysis and culture. Additionally, in atypical presentations (e.g., rapid onset, active urinary sediment, absence of diabetic retinopathy, or type 1 diabetes with very short duration), a renal biopsy may be considered to exclude other causes of kidney disease.
Routine Monitoring Recommendations
Major diabetes guidelines recommend:
- Annual UACR and serum creatinine/eGFR measurement in all patients with type 2 diabetes from diagnosis, and in type 1 diabetes patients after 5 years of disease duration
- Blood pressure monitoring at every clinical visit
- HbA1c measurement every 3–6 months
Treatment
The treatment of diabetic nephropathy rests on four fundamental pillars, all of which must be pursued simultaneously for optimal outcomes:
1. Cardiovascular Risk Reduction
Patients with diabetic nephropathy carry an extremely high risk of cardiovascular events (heart attack, stroke), often exceeding the risk of progressing to dialysis. Risk reduction strategies include:
- Smoking cessation: arguably the single most impactful lifestyle intervention, with benefits for both cardiovascular and renal outcomes
- Regular physical activity: improves insulin sensitivity, blood pressure, lipid profile, and body weight
- Dietary optimization: a heart-healthy diet (Mediterranean-style or DASH diet) low in saturated fat, refined sugars, and processed foods
- Statin therapy: for dyslipidemia management and cardiovascular risk reduction
- Weight management: in overweight or obese patients, even modest weight loss substantially improves metabolic and renal parameters
- Aspirin or antiplatelet therapy: in selected high-risk patients, as directed by their physician
2. Glycemic Control
Rigorous management of blood glucose remains the cornerstone of nephropathy prevention and the most powerful tool to slow its progression in early stages:
- Target HbA1c: generally <7% (53 mmol/mol) for most patients, though individualized targets are appropriate based on age, comorbidities, and risk of hypoglycemia
- Monitoring of glycated hemoglobin (HbA1c) every 3–6 months
Important Drug Considerations in Reduced Kidney Function
As eGFR declines, several antidiabetic medications require dose adjustment or must be discontinued:
- Metformin: the first-line oral agent for type 2 diabetes, is contraindicated when eGFR falls below 30 mL/min/1.73 m² due to the risk of potentially fatal lactic acidosis; dose reduction is recommended when eGFR is 30–45 mL/min/1.73 m²
- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin, canagliflozin): have demonstrated significant nephroprotective and cardioprotective effects beyond glucose lowering in patients with diabetic nephropathy, and are now recommended as part of standard care in eligible patients; they are not effective as glucose-lowering agents when eGFR is very low, but their renoprotective effects may persist at lower eGFR thresholds
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide): associated with cardiovascular and renal benefits; dose adjustments depend on the specific agent and degree of renal impairment
- NSAIDs (non-steroidal anti-inflammatory drugs): should be avoided or used with extreme caution in patients with reduced kidney function, as they constrict afferent renal arterioles, further reducing GFR and precipitating acute kidney injury
- Iodinated contrast media (used in CT scans and angiography): requires careful case-by-case evaluation; adequate hydration before and after the procedure and use of the lowest effective contrast dose are recommended
3. Blood Pressure Control
Target blood pressure in patients with diabetic nephropathy is generally <130/80 mmHg, though this should be individualized. Blood pressure control slows GFR decline, reduces proteinuria, and decreases cardiovascular risk.
4. Inhibition of the Renin-Angiotensin-Aldosterone System (RAAS)
RAAS inhibition is the pharmacological cornerstone of nephroprotection in diabetic nephropathy:
- ACE inhibitors (e.g., ramipril, enalapril, lisinopril) or Angiotensin Receptor Blockers (ARBs) (e.g., losartan, irbesartan, candesartan) are the first-line antihypertensive agents in diabetic patients with albuminuria, regardless of blood pressure levels
- They reduce intraglomerular pressure, directly decrease proteinuria, and slow the progression of nephropathy beyond their blood pressure-lowering effects
- Combining an ACE inhibitor and an ARB is not recommended due to increased risk of adverse effects without additional nephroprotective benefit
- Finerenone (a novel non-steroidal mineralocorticoid receptor antagonist): has demonstrated significant renal and cardiovascular benefits in patients with CKD and type 2 diabetes and is increasingly being incorporated into treatment guidelines
Dietary Modifications
Based on the nephrologist’s evaluation:
- Protein restriction: reducing dietary protein intake (typically to 0.8 g/kg/day) lowers the filtration burden on damaged nephrons and may slow disease progression
- Low-sodium diet: essential for blood pressure control and fluid balance
- Potassium and phosphate restriction: as dictated by blood levels and degree of kidney function impairment
End-Stage Renal Disease: Renal Replacement Therapy
When kidney function deteriorates beyond a critical threshold (eGFR <15 mL/min/1.73 m², or earlier if symptoms of uremia are present), renal replacement therapy becomes necessary:
- Hemodialysis: the most common form, typically performed three sessions per week
- Peritoneal dialysis: an alternative home-based dialysis modality
- Kidney transplantation: the preferred treatment for eligible patients, offering superior survival and quality of life compared to dialysis; in selected patients with type 1 diabetes, simultaneous pancreas-kidney (SPK) transplantation may be considered
Sources and Bibliography
- Centers for Disease Control and Prevention (CDC). Diabetes and Chronic Kidney Disease.
- Varghese RT, Jialal I. Diabetic Nephropathy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from PubMed
- Mayo Clinic. Diabetic nephropathy (diabetic kidney disease) - Symptoms and causes.
- American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321. DOI: 10.2337/dc24-S011
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022;102(5S):S1–S127.
- Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. American Journal of Kidney Diseases. 2014;64(4):510–533. DOI: 10.1053/j.ajkd.2014.08.001
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE trial). New England Journal of Medicine. 2019;380(24):2295–2306.
- Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD trial). New England Journal of Medicine. 2020;383(23):2219–2229.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetic Kidney Disease.
